Strategic medical plans, their objectives and the initiatives that deliver them. Every initiative must trace to an approved objective.
Active plans
Objectives on track / at risk / off track
| Plan | Product | Scope | Lifecycle stage | Period | Status | Version | Owner | Budget planned vs actual | Review date |
|---|---|---|---|---|---|---|---|---|---|
Lumeva Global Medical Plan FY2026 MP-2026-LMV-G | Lumeva | Global | Mature post-launch | FY2026 | Periodic review | v2 | EMDr. Elena Moretti | 80% $2.9M of $3.6M | 30 Sept 2026 |
| Objective | Product | Owner | Status | Progress | Confidence | Initiatives | Plan |
|---|---|---|---|---|---|---|---|
Publish real-world persistence and switching evidence across three markets. SO-LMV-01 | Lumeva | EMDr. Elena Moretti | On track | 80% | High | 1 | Lumeva Global Medical Plan FY2026 |
Support the chronic-migraine lifecycle extension with a scientific platform and pre-submission KOL… SO-LMV-02 | Lumeva | EMDr. Elena Moretti | On track | 57% | Medium | 1 | Lumeva Global Medical Plan FY2026 |
Reduce medical-information response time for dosing and interaction queries to a median of 2 busine… SO-LMV-03 | Lumeva | FAFatima Al-Sayed | At risk | 45% | Medium | 1 | Lumeva Global Medical Plan FY2026 |
| Initiative | Type | Product | Objective | Owner | Dates | Status | Priority | Progress | Budget vs spend |
|---|---|---|---|---|---|---|---|---|---|
| Publication project | Lumeva | SO-LMV-01 | DCDavid Chen | 15 Jan 2026 – 30 Nov 2026 | In progress | High | 82% | $58k / $70k | |
| Advisory board | Lumeva | SO-LMV-02 | EMDr. Elena Moretti | 01 Mar 2026 – 31 Dec 2026 | In progress | Medium | 58% | $121k / $160k | |
| Medical-information improvement | Lumeva | SO-LMV-03 | FAFatima Al-Sayed | 01 Apr 2026 – 31 Oct 2026 | At risk | Medium | 45% | $22k / $40k |